BCAL Diagnostics Limited (BDX.AX)
AUD 0.09
(-2.17%)
AUD 0.09
(-2.17%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 | -0.03 AUD | -8.33% |
| 2023 | -0.02 AUD | -44.58% |
| 2022 | -0.02 AUD | -133.8% |
| 2021 | -0.01 AUD | -121.88% |
| 2020 | -0.00 AUD | -60.0% |
| 2019 | -0.00 AUD | 9.09% |
| 2018 | -0.00 AUD | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q3 | -0.01 AUD | 25.96% |
| 2024 Q2 | -0.01 AUD | -100.0% |
| 2024 FY | - AUD | -8.33% |
| 2024 Q1 | -0.01 AUD | 57.38% |
| 2024 Q4 | -0.01 AUD | 0.0% |
| 2023 FY | - AUD | -44.58% |
| 2023 Q4 | -0.01 AUD | -96.77% |
| 2023 Q3 | -0.01 AUD | 47.01% |
| 2023 Q2 | -0.01 AUD | -98.31% |
| 2023 Q1 | -0.01 AUD | 41.0% |
| 2022 Q3 | -0.01 AUD | 14.06% |
| 2022 FY | - AUD | -133.8% |
| 2022 Q2 | -0.01 AUD | -113.33% |
| 2022 Q1 | -0.00 AUD | 50.0% |
| 2022 Q4 | -0.01 AUD | -81.82% |
| 2021 Q4 | -0.01 AUD | -36.36% |
| 2021 FY | - AUD | -121.88% |
| 2021 Q1 | -0.00 AUD | -11.11% |
| 2021 Q2 | -0.00 AUD | -10.0% |
| 2021 Q3 | -0.00 AUD | -300.0% |
| 2020 Q3 | -0.00 AUD | 65.22% |
| 2020 Q1 | -0.00 AUD | 0.0% |
| 2020 Q4 | -0.00 AUD | -12.5% |
| 2020 Q2 | -0.00 AUD | -4.55% |
| 2020 FY | - AUD | -60.0% |
| 2019 FY | - AUD | 9.09% |
| 2018 FY | - AUD | 0.0% |
| Name | Eps | Eps Difference |
|---|---|---|
| Australian Clinical Labs Limited | 0.12 AUD | 121.667% |
| Genetic Signatures Limited | -0.11 AUD | 76.364% |
| Genetic Technologies Limited | -0.09 AUD | 71.397% |
| Healius Limited | -0.98 AUD | 97.347% |
| Imagion Biosystems Limited | -0.41 AUD | 93.659% |
| Integral Diagnostics Limited | -0.26 AUD | 90.0% |
| INOVIQ Ltd | -0.07 AUD | 63.329% |
| Microba Life Sciences Limited | -0.05 AUD | 46.502% |
| Monash IVF Group Limited | -0.02 AUD | -54.762% |
| Rhythm Biosciences Limited | -0.03 AUD | 13.333% |
| Sonic Healthcare Limited | 1.07 AUD | 102.43% |